Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer

Brown, Zachary J.; Heinrich, Bernd; Steinberg, Seth M.; Yu, Su Jong; Greten, Tim F.

doi:10.1186/s40425-017-0298-2

Table 1 Clinical trials with immune checkpoint inhibitors and given adverse event profiles

From: Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer

Drug	Author	Tumor Type	Number of Patients	Taken off therapy secondary to toxicity	Death secondary to therapy	Elevation AST any grade	Elevation AST grade 3–4	Elevation ALT any grade	Elevation ALT grade 3–4	Diarrhea any grade	Diarrhea grade 3–4
Tremelimumab	Sangro et al. 2013 [14]	HCC	20	3	0	14	9	11	5	6	1
Tremelimumab + ablation	Duffy et al. 2016 [13]	HCC	32	4	0	11	7	6	3	2	0
Nivolumab	El-Khoueiry et al. 2017 [15]	HCC	262	9	0	26	14	24	8	32	3
Pembrolizumab	Garon et al. 2015 [33]	NSCLC	495	NR	NR	15	3	11	2	40	3
Pembrolizumab	Reck et al. 2016 [34]	NSCLC	154	11	1	NR	NR	NR	NR	22	6
Pembrolizumab	Herbst et al. 2016 [35]	NSCLC	682	32	6	17	2	24	3	52	6
Nivolumab	Borghaei et al. 2015 [36]	NSCLC	287	14	1	9	1	9	0	22	2
Nivolumab	Brahmer et al. 2015 [37]	NSCLC	131	4	0	2	0	2	0	10	0
Nivolumab	Rizvi et al. 2015 [38]	NSCLC	117	14	2	0	0	1	0	12	3
Ipilimumab	Wolchok et al. 2010 [39]	Melanoma	214	35	0	NR	NR	NR	NR	66	14
Ipilimumab	Hodi et al. 2010 [23]	Melanoma	131	17	4	1	0	2	0	46	13
Ipilimumab	Robert et al. 2015 [40]	Melanoma	256	24	1	6	2	9	2	79	26
Ipilimumab	Eggermont et al. 2015 [22]	Melanoma	471	245	5	78	20	102	25	270	81
Ipilimumab	Larkin et al. 2015 [41]	Melanoma	311	46	1	12	5	11	2	139	46
Tremelimumab	Camacho et al. 2009 [42]	Melanoma	89	10	0	NR	NR	NR	NR	34	13
Tremelimumab	Ribas et al. 2013 [43]	Melanoma	325	43	7	NR	NR	NR	NR	166	60
Tremelimumab	Kirkwood et al. 2010 [44]	Melanoma	246	13	2	NR	NR	NR	NR	99	28
Pembrolizumab	Robert et al. 2014 [45]	Melanoma	173	6	0	5	0	6	0	22	1
Pembrolizumab	Robert et al. 2015 [40]	Melanoma	555	30	0	20	1	16	1	102	21
Pembrolizumab	Ribas et al. 2015 [46]	Melanoma	357	17	0	NR	NR	NR	NR	34	2
Nivolumab	Topalian et al. 2014 [47]	Melanoma	107	17	0	4	0	5	0	19	2
Nivolumab	Robert et al. 2015 [48]	Melanoma	210	14	0	2	1	3	2	33	2
Nivolumab	Weber et al. 2015 [49]	Melanoma	268	7	0	11	1	7	2	30	1
Nivolumab	Larkin et al. 2015 [41]	Melanoma	313	24	1	12	3	12	4	64	9
Nivolumab	Weber et al. 2016 [50]	Melanoma	92	0	0	5	0	6	0	39	1

HCC Hepatocellular Carcinoma, NSCLC Non-small cell lung cancer, AST aspartate aminotransferase, ALT alanine aminotransferase, NR not reported

Back to article page